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Abstract 
A significant amount of information is available linking consumption of milk proteins with the 
beneficial modulation of key outcomes associated with diet related conditions such as 
cardiovascular disease, obesity and type two diabetes. While intact milk proteins per se may have 
some direct health promoting effects, the functional food potential of dairy proteins is mainly 
attributed to the peptides formed following hydrolysis. Evidence/emerging evidence for the 
potential role of dairy peptides as hypotensive, mineral binding, immunomodulatory, anticancer, 
opioid agonist and antagonist, antimicrobial, gut health enhancing, hypo-cholesterolemic, 
insulinotrophic and neuromodulatory agents now exists. Some information outlining the 
biofunctional potential of caseinophosphopeptides (CPPs) is presented herein. 
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Introduction 
The terms “functional foods” and “nutraceuticals” are relatively broad and need to be carefully 
defined. Their meaning may be distinguished on the basis that they describe foods/food 
ingredients which on the one hand have potential disease preventative versus disease curative 
roles, i.e., functional foods and nutraceuticals, respectively. In both cases, functional foods and 
nutraceuticals are foods/food ingredients that contain biofunctional components which may 
beneficially modulate physiological functions. Furthermore, in order for these components to 
have an effect in vivo, the bioactive components must be bioavailable, i.e., they must reach the 
target site/organ in sufficient amounts to have a physiological effect. The real distinction between 
the two is that functional foods are ultimately foods whereas nutraceuticals, having potential 
disease curative functions, could be considered as drug-like agents. There are also instances 
where the above two terms may be confused with technofunctional foods/ingredients. This term 
relates to foods or ingredients which confer specific technofunctional properties such as 
emulsification, foaming, gelation, water-binding, aggregation properties, etc., to foods. 
There is a growing interest in biofunctional foods/food ingredients given their potential in the 
prevention of chronic diseases. From a consumer perspective, biofunctional foods are associated 
with the general concept of ‘wellness’ and lifestyle choice where an individual may choose to 
consume specific foods/food ingredients based on their ability to modulate controllable risk 
factors associated with various chronic diseases. These include diseases/conditions such as 
cardiovascular disease, diabetes and obesity. Biofunctional foods are therefore a growing global 
market and as a consequence represent a real opportunity for diversification and innovation in the 
food sector. 
It is well documented that intact milk proteins possess many potential bioactivities. These include 
the antibacterial activity associated with the whey protein lactoferrin. Milk proteins, in addition, 
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contain an extensive range of bioactive peptide sequences which are encrypted within their 
primary structures (FitzGerald and Meisel, 2003). As a consequence, different milk protein-
derived peptides are being marketed as biofunctional foods and ingredients which may 
beneficially modulate the physiological responses of different systems within the human body. 
Nevertheless, some conflicting evidence exists in relation to the efficacy of these biofunctional 
peptides. This article presents some of the scientific information with respect to 
caseinophosphopeptides (CPPs), casein derived phosphorylated peptides, as a means to 
ascertaining those parameters which may dictate the overall bioactivity of milk protein-derived 
biofunctional peptides. It is proposed that this exercise may provide some useful insights for the 
development of peptides as biofunctional ingredients for the reduction of chronic disease risk. 
1 Physiological targets of milk bioactive peptides 
Beyond their basic nutritional role in the provision of nitrogen and essential amino acids, milk 
proteins and peptides have the potential to beneficially modify a range of different physiological 
systems within the human body. Milk protein-derived bioactive peptides may, for example, 
modulate control systems involved in the cardiovascular, nervous, gastrointestinal and immune 
systems. The general mode of action is that these peptides ultimately alter specific interactions 
involving cellular receptors or enzymes which lead to the induction of a physiological response. 
Therefore, the targeted utilisation of these peptides can beneficially modulate physiological 
systems within the human body. A diverse range of potential physiological targets have been 
identified, mostly using in vitro assays to date, for peptide sequences which are encrypted within 
the primary structures of the milk proteins. These include peptides having immunomodulatory, 
opioid, mineral binding/bone formation, hypotensive, antithrombic, anticancer, etc, properties 
(Clare and Swaisgood, 2000; FitzGerald and Meisel, 2003; Korhonen and Pilhanto, 2006). 
Milk bioactive peptides have significant potential to modulate various human health conditions 
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via their application as health promoting and disease risk reducing agents. Furthermore, these 
peptides have possible synergistic effects in human health maintenance. The application of 
bioactive peptides to modulate various conditions associated with the metabolic syndrome is one 
such example. The so-called metabolic syndrome is manifested in conditions associated with 
dyslipidemia, impaired glucose metabolism, central obesity and hypertension. It is interesting to 
note that for each of these conditions, one or more milk-derived peptides may exist which could, 
individually or indeed in synergy, beneficially modulate these conditions (Figure 1). Looking at 
cardiovascular disease, for example, it has been shown (at least in vitro and in some instances in 
vivo) that different milk protein-derived peptides display angiotensin converting enzyme (ACE) 
inhibitory, antithrombotic, anti-inflammatory, mineral binding and anti-oxidant activities. All 
these activities have the potential to reduce the incidence of controllable risk factors associated 
with cardiovascular disease. In addition to conditions associated with the metabolism syndrome, 
Figure 1 shows that opioid peptides and CPPs may play a role in the reduction of stress and poor 
bone health, respectively. 
 
Since these bioactive peptides are encrypted within the primary structures of the different milk 
proteins they must first be released in order to become active. A number of different release 
approaches exist as follows: 
- in vitro hydrolysis following a targeted enzymatic route using proteolytic activities from 
mammalian, microbial and plant sources or via the utilisation of physical and/or chemical 
processes such as ultrasonic, microwave and chemical treatments. 
- hydrolysis by bacterial proteolytic/peptidolytic activities during the manufacture of 
fermented dairy products. Such hydrolysis may also occur in vivo following the action of 
intestinal microflora naturally found in the human body. 
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- in vivo digestion via the combined action of gastric and pancreatic hydrolases during 
gastrointestinal transit following oral ingestion. Subsequently, epithelial and serum 
peptidases may mediate further degradation assuming transport across the intestinal 
mucosa and transfer into the serum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Summary of milk peptides that may beneficially modulate lifestyle diseases and 
conditions. (ACE: angiotensin converting enzyme; CPPs: Caseinophosphopeptides) 
 
The translation of in vitro/ex vivo observations in relation to a particular bioactive peptide to 
ingredients/products beneficial to human health represents a major scientific challenge. Detailed 
analysis of the scientific information in connection with the application of CPPs as mineral 
bioavailability enhancement agents provides some critical insights into the above. 
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2 CPPs 
A range of CPP ingredients and CPP containing products are currently available in the 
marketplace (Table 1). These CPPs originate from the four caseins found in bovine milk. 
 
Table 1. Some commercial ingredients and products containing caseinophosphopeptides (CPPs). 
 Manufacturer Format 
Ingredients   
CE90CPP DMV, International ingredient 
Lacprodan D1-2021 Arla Foods ingredient 
Peptigen 110 MD Foods ingredient 
Capolac Arla Foods ingredient 
CPPB and CPPC  Armor Proteins ingredient 
CPP-I, II & III Meiji Seika ingredient 
Recaldent Cadbury Adams ingredient 
Products   
Tekkotsu Inryou Suntory soft drink 
Kotsu Calcium Asahi soft drink 
MI Paste & MI Paste Plus GC, America tooth paste 
 
CPPs are encrypted within the primary sequences of caseins and may be released following the 
approaches already described. They correspond to peptide fragments which are rich in clusters of 
phosphorylated seryl (and occasionally threonine) residues. They are reported to improve mineral 
bioavailability by acting as a mineral carrier and/or by enhancing mineral solubility. The caseins 
are phosphorylated during milk biosynthesis via the activity of specific kinases present in the 
mammary gland (FitzGerald, 1998). The number of serine/threonine phosphate groups may be 
influenced by genetic polymorphism of the proteins. Therefore, different levels of 
phosphorylation may be observed in the individual caseins as follows:  
- s1-casein: 8-9 phosphate groups 
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- s2-casein: 10-13 phosphate groups 
- -casein: 5 phosphate groups 
- and -casein: 1-2 phosphate groups. 
The two most studied CPPs originate from s1- and -casein. Both of these CPPs, i.e., s1-casein 
f(59-79)5P and -casein f(1-25)4P), contain a specific sequence know as the “acidic motif”. This 
motif consists of 3 serine phosphate groups followed by two glutamic acid residues (Figure 2). At 
neutral pH, the “acidic motif” is a highly charged region and this has been linked with the ability 
of CPPs to bind minerals (Ca
2+
, Zn
2+
, Fe
2+
, Mn
2+
, etc.). CPPs have been reported to improve 
dietary bioavailability of those bivalent cations and as a consequence CPPs may play a major role 
in modulating mineral uptake and bone formation. CPPs have also been associated with 
anticariogenic effects in addition to promoting remineralisation of dental enamel (Reynolds, 
1997). Apart from their mineral binding properties, CPPs are also reported to have 
immunomodulatory and antioxidant properties. 
 
 
 
 
 
Figure 2. Peptide sequence of tryptic caseinophosphopeptides (CPPs) from s1-casein f(59-
79)5P and -casein f(1-25)4P highlighting the “acidic motif”(fragment underlined in the 
sequence). 
 
s1-casein f(59-79)5P
Gln-Met-Glu-Ala-Glu-Ser(P)-Ile-Ser(P)-Ser(P)-Ser(P)-Glu-Glu-Ile-Val-Pro-Asn-Ser(P)-Val-Glu-Gln-Lys
-casein f(1-25)4P
Arg-Glu-Leu-Glu-Glu-Leu-Asn-Val-Pro-Gly-Glu-Ile-Val-Glu-Ser(P)-Leu-Ser(P)-Ser(P)-Ser(P)-Glu-Glu-Ser-Ile-Thr-Arg
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Several studies performed in mammals including humans, pigs and rats have demonstrated the in 
vivo formation of CPPs following ingestion of milk and dairy products (Table 2). CPPs have been 
found in the distal small intestine of rat, and in the stomach, duodenum and distal ileum of human 
subjects (Hartmann and Meisel, 2007) following the consumption of dairy ingredients and 
products. 
 
Table 2. Examples of studies reporting the formation of caseinophosphopeptides (CPPs) in vivo 
following the ingestion of milk and dairy products (adapted from FitzGerald (1998)) 
System Diet CN origin Reference 
 
Rat 
(small intestine) 
CN nd Naito et al. (1972) 
Minipig 
(jejunal fluid) 
CN s1-CN Meisel and Frister 
(1988) 
Human 
(stomach and duodenum) 
milk/yoghurt s1/-CN Chabance et al. 
(1998) 
Human 
(ileostomy fluid) 
milk/CPPs nd Meisel et al. (2003) 
(CN: casein; nd: not determined) 
 
Despite the fact that CPPs are present in the gastrointestinal system following dairy protein or 
CPPs ingestion, conflicting evidence exists in the literature regarding the relationship between 
Ca
2+
 absorption and CPP consumption. Some studies have demonstrated a positive role for CPPs 
on Ca
2+
 absorption while others have shown no effect (Table 3). 
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Table 3. Summary of the action of caseinophosphopeptides (CPPs) on Ca2+ bioavailability (+: 
increase in the Ca
2+
 bioavailability; no effect: no improvement in the Ca
2+
 bioavailability). 
Adapted from FitzGerald (1998) and Meisel et al. (2003). 
Subject Study type Method Result 
 
rachitic children in situ Ca
2+
 balance + 
rat in situ Ca
2+
 balance + 
rat in situ Ca
2+
, tube ligation + 
chicken in situ Ca
2+
, tube ligation + 
rat in vivo bone measurement no effect 
pig in vivo Ca
2+
 solubilisation + 
rat in vivo Ca
2+
 balance no effect 
pig in vivo bone mineralisation no effect 
human in vivo absorption + 
rat embryonic bone in vitro bone deposition + 
human (post-menopausal) in vivo absorption + 
human in vivo absorption + 
human in vivo absorption no effect 
 
3 Parameters influencing CPP modulated mineral bioavailability 
The different outcomes from studies carried out on Ca
2+
 bioavailability in the presence of CPPs 
may find their origin in several parameters. The conflicting bioavailability results may be due to 
differences in the methodology utilised for mineral quantification, the presence of chelating 
agents such as phytates, the food matrix, CPP preparation, CPP dose or CPP:mineral ratio. 
Aspects of the last four parameters will be discussed in the following sections. 
3.1 Food matrix effects on mineral bioavailability 
Since CPPs are being used as ingredients or additives for their mineral binding properties they are 
generally formulated in a food matrix. However, different studies have shown that components 
within the food matrix may play a significant role in the bioavailability of dietary minerals. For 
instance, the presence of inorganic phosphate (Pi) may lead to a decreased absorption of dietary 
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Ca
2+
due to the formation of insoluble calcium phosphate complexes. However, on inclusion of 
CPPs, the bioavailability of dietary Ca
2+
 may be maintained in the presence of phosphate. In a rat 
ileum model the absorption of Ca
2+
 by (Pi) decreased by 40% at a Ca:Pi = 1:1 and was decreased 
by 60% at a Ca:Pi = 1:2 in the presence of CPPs. However, in the absence of CPPs Ca
2+
 
absorption decreased by 90% at a Ca:Pi = 1:1 and was decreased by 97% at a Ca:Pi = 1:2 (values 
compared to the absorption of Ca
2+
 from CaCl2 in the absence of Pi, Erba et al. (2001)). This 
specific example clearly demonstrates that the absorption of Ca
2+
 from a medium containing Pi 
can be significantly maintained in the presence of CPPs. 
CPPs have been detected in the intestinal fluid of humans with an ileostomy. Higher levels were 
detected after ingestion of milk as compared to none or very low CPP levels detectable following 
CPPs ingestion (Meisel et al., 2003). The results from this study therefore indicate that milk has a 
protective effect against CPP degradation in the gastrointestinal tract. Surprisingly, direct 
ingestion of CPPs resulted in their almost total degradation and as a consequence they were only 
detected at very low levels in the ileum fluid. Food matrix therefore influences the stability of 
bioactive peptides in this case the stability of CPPs. 
In other studies, fruit beverage appears to have the ability to protect CPPs against degradation by 
gastrointestinal enzymes. A fruit beverage (a mixture of 7.2% grape concentrate, 4.2% orange 
concentrate, 24.5% apricot puree, 5.1% sugar, 0.35% pectin, 0.054% L-ascorbic acid and 58.7% 
osmosis water) was supplemented with either milk or CPPs and it was subsequently subjected to 
simulated gastro intestinal digestion (SGID) using a combination of gastric and pancreatic 
enzyme activities (García-Nebot et al., 2009). Subsequent to SGID, 10 different CPPs, with one 
presenting the “acidic cluster”, were identified in the fruit beverage sample supplemented with 
milk. However, when CPPs were added to the fruit beverage, 16 different CPPs were identified 
following SGID with more than one peptide containing the acidic cluster sequence (Figure3). 
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These results indicate that fruit beverages may be good vehicles/matrices for the delivery of 
CPPs. 
 
 
 
 
 
 
 
Figure 3. Release/retention of caseinophosphopeptides (CPPs) following simulated gastro 
intestinal digestion (SGID) of fruit beverage supplemented with either milk or CPPs. Adapted 
from García-Nebot et al. (2009) 
 
Clear evidence therefore exists on differences in the relative stability of CPPs during in vivo and 
in vitro digestion. These findings highlight the need to assess/validate both the stability and the 
bioactivity of biofunctional peptides within the food delivery matrix. As already mentioned, there 
may be a need for the application of specific reformulation and/or protective methodologies (such 
as encapsulation) if the biofunctional peptide is not stable in a given food matrix. 
3.2 Influence of CPP preparation 
The nature of the CPP preparation is another important factor that may affect its ability to 
modulate mineral bioavailability. Differences in the mineral uptake promoting potential of s1-
casein f(59-79)5P and -casein f(1-25)4P have been reported. For example, a higher number of 
HT29 epithelial cells responsive to Ca
2+
 uptake was found with -casein f(1-25)4P than with s1-
Fruit 
beverage
Milk
Fruit 
beverage
CPP
10 different CPPs
1 SpSpSpEE cluster
16 different CPPs
> 1 SpSpSpEE cluster
SGID SGID
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casein f(59-79)5P (Ferrarretto et al., 2003). This result may be linked to differences in the 
binding affinity for Ca
2+
 by these two particular fragments. It was shown that -casein f(1-25)4P 
had a lower Ca
2+
 binding affinity and higher stoichiometry (Ca
2+
: peptide, 0.85 mM
-1
 and 4 
Ca
2+
:peptide, respectively) than s1-casein f(59-79)5P which had a higher binding affinity and 
lower stoichiometry (0.63 mM
-1
 and 1 Ca
2+
:peptide, respectively) (Meisel and Olieman, 1998). 
Similarly, iron uptake by Caco-2 intestinal cell cultures and rat duodenal loop has been shown to 
depend on the CPP preparation, being about 2 fold higher with -casein f(1-25)4P than with s1-
casein f(59-79)5P (Kibangou et al., 2005).  
In addition to the milk protein source of the CPP, peptide sequence may also play an important 
role on mineral bioavailability modulation. It has been demonstrated that Ca
2+
 uptake by 
intestinal cells depends on amino-acid residues upstream and downstream from the “acidic 
motif”. The central role of the phosphorylated acidic domain and of the N-terminal region of -
casein f(1-25)4P have been clearly demonstrated (Ferrarretto et al., 2003). Removal of 
phosphorus residues or removal of the N terminal region yielding -casein f(17-25)3P both 
resulted in a dramatic decrease in Ca
2+
 uptake by HT29 cells. This result indicates that further 
degradation of the CPPs once released in vivo following gastrointestinal digestion may 
significantly affect Ca
2+
 uptake by intestinal cells and may even result in a complete loss of Ca
2+
 
uptake. Similarly, these results indicate during the generation of CPPs in vitro, that optimum 
conditions (hydrolysis or fermentation) must be employed in order to release peptide fragments 
which retain biofunctionality. 
3.3 Influence of CPP dose and CPP:mineral ratio 
CPP dose and CPP:mineral ratio have also been demonstrated to affect Ca
2+
 uptake by intestinal 
cells. At constant extracellular Ca
2+
, a dose-response relationship was reported between the 
concentration of -casein f(1-25)4P (from 50 to 200 mol L-1) and Ca2+ uptake by HT29 cells. 
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However, no similar dose-response relationship was observed for s1-casein f(59-79)5P 
(Gravaghi et al., 2007). Additional to CPP dose, the concentration of extracellular Ca
2+
 also 
affects Ca
2+
 uptake by HT29 cells, with maximal biological activity being observed at 4 mmol L
-1
 
extracellular Ca
2+
. A further increase in extracellular Ca
2+
 concentration (6 mmol L
-1
) resulted in 
a decrease in the Ca
2+
 uptake by the HT29 cells. In this specific example, optimum conditions for 
Ca
2+
 uptake by HT29 cells were 4 mmol L
-1
 extracellular Ca
2+
 and 200 mol L-1 -casein f(1-
25)4P. 
The extracellular Ca
2+
 concentration was also shown to affect the formation of CPP aggregates. 
Both -casein f(1-25)4P and s1-casein f(59-79)5P formed aggregates in the presence of Ca
2+
 
having similar hydrodynamic radii (60 nm). However, the main difference originated from the 
relative concentration of -casein f(1-25)4P aggregates (100%) as compared to that of s1-casein 
f(59-79)5P) (4.5%) in the presence of 4 mmol L
-1
 extracellular Ca
2+
. Ca
2+
 is required for the 
formation of these aggregates as its binding to CPPs results in lower electrostatic repulsion and/or 
higher intermolecular bonds enabling the formation of supramolecular structures. The lesser 
extent of aggregate formation with s1-casein f(59-79)5P was postulated to be due to higher 
electrostatic repulsions as this fragment possesses more negatively charged phosphorylated 
groups compared to -casein f(1-25)4P. The aggregation and Ca2+ uptake behaviour of CPPs 
were superimposable, suggesting that the bioactive form of -casein f(1-25)4P may be 
aggregated (Gravaghi et al., 2007). 
The above represent just some of the parameters which contribute to the efficacy of CPPs. It is 
worth noticing that other factors exist and that the ultimate physiological effect observed may be 
a cumulative response to multiple, even opposing, effects. 
4 Some conclusions relative to peptide biofunctionality 
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The different aspects addressed herein relative to the biofunctionality of CPPs may be extended 
to other bioactive peptides originating from milk and alternative biological materials. Some of the 
main lessons learnt to date during the study of bioactive peptides may be summarised as follows: 
• numerous factors affect the potential of peptides to act as biofunctional agents as 
illustrated with the specific example of CPPs. The conflicting reports relative to the ability 
of CPPs to beneficially modulate mineral bioavailability may be related to the 
methodology employed, food matrix, peptide structure, dose utilised and potency 
differences between preparations, etc. 
• while bioactivity may be demonstrated in vitro it is important to appreciate that peptides 
are sensitive biological materials which can be degraded or altered during different steps 
in food processing and then later on during food digestion and/or during transport in the 
blood stream. These different steps must be accounted for when addressing the bioactivity 
of milk peptides as minor changes in peptide sequence may result in a complete loss in 
their bioactivity. 
• the mechanisms of action governing many bioactivities are still poorly understood and a 
greater understanding of same may lead to a more targeted utilisation of bioactive 
peptides within functional/formulated food systems. In addition, knowledge of the 
mechanism(s) of action is a key element in discovery of novel bioactive peptide 
sequences. 
• the fact that peptides may display multifunctional bioactivities needs to be considered as 
some peptides may have several actions within the body. This multifunctionality may lead 
to synergetic effects. 
• finally, regulatory requirements are important as these will ultimately dictate success in 
the development of new bioactive peptides or new applications of these ingredients for the 
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marketplace. Not alone must bioactive peptides be effective, they must be safe for 
consumption and abide by the regulations in place for the specific application (food 
matrix) in the target market associated with a given geographical location. These 
regulatory aspects are addressed in the regulation on nutrition and health claims adopted 
in December 2006 by the EU to ensure that health claims on foods were supported by 
scientific evidence. The regulation verified by EFSA includes different aspects such as 
“general function“ in article 13.1, “new function” health claims in article 13.5 and “claims 
regarding disease risk reduction and child development or health” in article 14. 
In summary, bioactive peptides represent complex additives/ingredients that must be studied in 
the context of their final utilisation in order to confirm their potential to modulate specific 
functions within the human body. 
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